Paxlovid is a recommended treatment option for mildly ill COVID-19 patients (patients who do not require new or additional supplemental oxygen from their baseline status) who:
Antimicrobial class: Antiviral (Paxlovid is a ritonavir boosted SARS-CoV-2 main protease inhibitor (nirmatrelvir) that prevents viral replication)
Half-life: ~6 hours (longer in those with renal impairment)
Metabolism: Ritonavir is a potent inhibitor of CYP3A4 and various drug transporters (e.g. P-glycoprotein). Ritonavir and nirmatrelvir are both CYP3A4 substrates
Excretion: renal primary route (nirmatrelvir); hepatic primary route (ritonavir)